ArticleJournal of the American Heart Association2026
Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial Dysfunction at the Intersection of CKM Syndrome: Molecular Mechanisms and Path-to-Target Therapies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethylmalonic acid (MMA) is regarded a biomarker of aging, oxidative stress, and mitochondrial dysfunction, which are also pathophysiological mechanisms that underlying cardiovascular-kidney-metabolic (CKM) syndrome. Nevertheless, the relationship between MMA per se and CKM remains unclear.
methodsThis prospective cohort study was based on data from the National Health and Nutrition Examination Survey (1999-2018). Multinomial logistic regression was conducted to evaluate the relationship between MMA and CKM stages. Hazard ratios (HRs) and 96% CI for the association between MMA and mortality were calculated using the multivariable Cox regression model. The mediating role of MMA on the association between cardiometabolic biomarkers and mortality was estimating using mediation analysis.
resultsThe cohort included 14 581 participants with CKM (median age, 55.0 [interquartile range, 41.0-69.0] years; 52.4% male). MMA showed a significant association with CKM stages (odds ratio, 3.73 [95% CI, 3.47-4.01]) after adjustment for multivariate covariates. During the median follow-up of 102 months (interquartile range, 76-202), 3738 deaths occurred. Compared with participants in the lowest MMA quartile, those in the highest MMA quartile had HRs of 2.03 (95% CI, 1.78-2.30) for all-cause death mortality, 2.31 (95% CI, 1.81-2.95) for cardiovascular mortality, and 1.92 (95% CI, 1.65-2.23) for noncardiovascular mortality, consistent with results in the CKM stage 1 to 2 and 3 to 4 groups. Furthermore, MMA mediated the association between several cardiometabolic biomarkers, such as physical activity, frailty, Life's Simole 7 score, and estimated glomerular filtration rate levels, and mortality outcomes in the population with CKM.
conclusionsMitochondria-derived MMA may serve as a valuable biomarker for evaluating CKM progression and mortality risk in individuals with CKM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.